reason report
outlook
bottom line remain op view
major popul develop emerg world
like touch one genet test lifetim
creat massiv market benefit deliv
solid y/i revenue growth vs us street quarter lift
pressur impli steep ramp still maintain full-
year revenue guid beat actual driven servic revenu
ivd licens agreement nr vs tradit
consum instrument beat larg in-lin investor
bound view low-qual beat us outlook
increasingli lever nh nation health servic uk whole
genom initi uk biobank alreadi gener data
genom project link remain op pt
nh whole genom sampl key outlook pop-
seq applic becom next major growth driver
recal nh previous announc would sequenc
individu uk next year drive practice-chang
approach util genom clinic project unrel
genom uk biobank project highlight
link announc call high degre
confid nh project happen iron
detail ramp ahead believ popul sequenc
next major applic expans bound drive
growth next year
elast demand play custom transit
larger platform address increasingli capac lower
cost saw nextseq pull-through lower end
rang miseq pull-through end rang
believ larg due custom transit
higher capac instrument miseq nextseq nextseq
novaseq access capac lower cost much line
expect elast demand see market
remain confid sampl come tabl
revenu guid maintain full year eye
view conserv impli
revenu ep estim move
reflect increas conservat around desktop consum
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep exclud charg amort intang
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
rate share outperform price target believ
major popul develop emerg world like touch one
genet test lifetim creat massiv market believ stand
benefit market compani see sequenc market
number sampl depth coverag expand dramat next year
novaseq upcom instrument drive signific reduct sequenc cost
earlier hiseq current novaseq flow cell like
futur set path genom price beyond high throughput
platform also continu drive double-digit growth desktop system includ nextseq
essenti key high growth market includ non-invas pre-nat test nipt
faster turn-around sampl oncolog continu domin sequenc
market world-wide life scienc genet test reproduct health oncolog
market share revenu market share sequenc unit believ ilmn
market share accuraci throughput enterpris level servic product factor
continu keep custom bound despit custom consid higher
price still direct strong competit sight somewhat unbound market
believ continu domin next-gen sequenc keep drive sequenc cost
lower lead elast demand sampl deeper sequenc need
share current trade price-to-earnings consensu ep
multipl view potenti unbound market opportun
major popul develop develop world like touch
sequenc form test next year use dcf analysi beta
long-term growth rate wacc arriv price target
believ remain strong forc sequenc market see revenu growth
continu outer year addit believ long-term growth rate
conserv estim given sequenc repres somewhat unbound market
opportun view still applic continu explor beyond
current one
margin profil would face downward pressur given new entrant innov competitor
understand domin market share genom sequenc industri
tmo ion torrent main competit believ major
competit near term product instal expens
competitor given near-monopoli howev custom balk price major
innov develop futur expect gross oper margin
declin given competit note occupi market share industri
instal base due expens equip instal highlight
import price consum elast product
affect reimburs decis medicar although posit cash
flow critic mass instal base demand genom test product
affect reimburs rate declin reimburs like lead lower demand
product activ turn would affect usag consum product
seen effect reimburs rate chang peer genom test industri
drop would certainli impact revenu believ ilmn growth profil could
significantli slow reimburs rate lower would like contribut
regul fda could major impact revenu well current
sell diagnost product laboratori consid laboratori develop test
ldt fda yet regul ldt due prolifer product
industri fda may revers cours regul ldt addit product requir
fda approv intend use diagnosi diseas
expand product purpos subject greater test complianc
standard increas oper expens believ addit regul
ilmn ldt research-us product would result risk estim
high level capit expenditur involv oper mean disrupt capital-expenditure
spend could lead slower growth level capital-expenditure need launch support new
product import growth slight delay instrument shipment
consum could caus guidanc miss miss guidanc close
one less hiseqx system anticip given small room error
one deal leverag capital-expenditure maintain oper risk
increas bp
revenu vs
slightli vs
improv bp
revenu vs fy
good sold
interest expens incom
add net incom attribut non-control interest
net incom attribut
sg sale
 sale
oper expens sale
sg revenu
 revenu
compani report svb leerink estim
